Here's a look at how VC funding in both spaces has been on a steady upward trajectory since 2010.
Just 16 biotech companies have raised more than $200 million in a venture capital round since the start of the decade, with 23andMe's financing marking the eighth-largest investment in that timeframe. Meanwhile, biotech has cruised past its previous VC funding record of $7.3 billion set in 2015, racking up about $9.3 billion this year across 471 deals, per the PitchBook Platform.
As for genetics companies, they have raised $1.5 billion across 68 deals with at least one VC participating since the start of the year. The previous record for VC funding in genetics companies in a single year was about $1.4 billion in 2015; before that, it was $991 million. Recent rounds include a $240 million Series B for
WuXi NextCODE, a platform for genomic sequence data, and $80 million for
Counsyl, the provider of genomics and DNA screening technology.
Perhaps the success of consumer genetics company 23andMe—one of the few genetics unicorns—will encourage even more VCs to segue into new territory.